Incannex Healthcare (IXHL) Proxy Filing summary

Executive summary

• Special meeting scheduled for May 27, 2025, to be held virtually, focusing on key proposals impacting capital structure, equity incentives, and compliance with Nasdaq requirements.

• Proposals include approval of a large issuance of shares underlying Series A Warrants, a significant increase in authorized common stock, amendments to the equity incentive plan, a potential reverse stock split, and adjournment flexibility.

• Board recommends voting in favor of all proposals to maintain Nasdaq listing, support future financing, and align compensation with performance.

Voting matters and shareholder proposals

• Proposal 1: Approve issuance of up to 347,222,700 shares underlying Series A Warrants from a March 2025 private placement, as required by Nasdaq Listing Rule 5635(d).

• Proposal 2: Amend certificate of incorporation to increase authorized common stock from 100,000,000 to 800,000,000 shares.

• Proposal 3: Amend 2023 Equity Incentive Plan to add 2,700,000 shares and an evergreen provision for future increases.

• Proposal 4: Approve a reverse stock split at a ratio between 1-for-2 and 1-for-50, with the board setting the exact ratio.

• Proposal 5: Approve adjournment of the meeting if more time is needed to solicit votes.

• All proposals require a majority vote, with specific rules for abstentions and broker non-votes.

Board of directors and corporate governance

• Board retains discretion to set the reverse split ratio and to abandon the split if deemed not in the best interest of shareholders.

• Board and compensation committee oversee the equity incentive plan and its amendments.

• Stockholders can communicate with the board via the corporate secretary; procedures for stockholder proposals and director nominations are outlined.